vs
Immunovant, Inc.（IMVT）与Marygold Companies, Inc.（MGLD）财务数据对比。点击上方公司名可切换其他公司
Immunovant, Inc.的季度营收约是Marygold Companies, Inc.的1.1倍（$8.4M vs $7.6M），Marygold Companies, Inc.净利率更高（-7.5% vs -899.0%，领先891.5%），Immunovant, Inc.同比增速更快（140.7% vs -4.5%）
Immunovant是一家临床阶段生物制药企业，专注于开发用于治疗严重、罕见自身免疫性疾病及炎症性疾病的新型单克隆抗体疗法，其核心在研候选产品覆盖多种自身免疫适应症，面向全球医疗市场布局研发管线。
Marygold Companies, Inc.是一家总部位于美国的多元化控股企业，核心业务覆盖金融服务、特种制造及消费品三大板块，主要面向北美市场开展运营，通过对旗下子公司的战略投资与运营优化实现长期价值增长。
IMVT vs MGLD — 直观对比
营收规模更大
IMVT
是对方的1.1倍
$7.6M
营收增速更快
IMVT
高出145.3%
-4.5%
净利率更高
MGLD
高出891.5%
-899.0%
损益表 — Q4 FY2024 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $8.4M | $7.6M |
| 净利润 | $-75.3M | $-576.0K |
| 毛利率 | — | 74.0% |
| 营业利润率 | -896.2% | -8.3% |
| 净利率 | -899.0% | -7.5% |
| 营收同比 | 140.7% | -4.5% |
| 净利润同比 | -26.7% | 67.0% |
| 每股收益（稀释后） | $-0.50 | $-0.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IMVTMGLD
| Q4 25 | — | $7.6M | ||
| Q3 25 | — | $7.0M | ||
| Q2 25 | — | $7.2M | ||
| Q1 25 | — | $7.0M | ||
| Q4 24 | — | $8.0M | ||
| Q3 24 | — | $7.9M | ||
| Q2 24 | — | $8.3M | ||
| Q1 24 | $8.4M | $7.9M |
净利润IMVTMGLD
| Q4 25 | — | $-576.0K | ||
| Q3 25 | — | $-356.0K | ||
| Q2 25 | — | $-1.5M | ||
| Q1 25 | — | $-1.0M | ||
| Q4 24 | — | $-1.7M | ||
| Q3 24 | — | $-1.6M | ||
| Q2 24 | — | $-1.9M | ||
| Q1 24 | $-75.3M | $-529.0K |
毛利率IMVTMGLD
| Q4 25 | — | 74.0% | ||
| Q3 25 | — | 77.0% | ||
| Q2 25 | — | 67.8% | ||
| Q1 25 | — | 75.0% | ||
| Q4 24 | — | 74.1% | ||
| Q3 24 | — | 73.1% | ||
| Q2 24 | — | 72.5% | ||
| Q1 24 | — | 70.5% |
营业利润率IMVTMGLD
| Q4 25 | — | -8.3% | ||
| Q3 25 | — | -18.2% | ||
| Q2 25 | — | -16.5% | ||
| Q1 25 | — | -21.4% | ||
| Q4 24 | — | -22.8% | ||
| Q3 24 | — | -27.4% | ||
| Q2 24 | — | -33.3% | ||
| Q1 24 | -896.2% | -18.7% |
净利率IMVTMGLD
| Q4 25 | — | -7.5% | ||
| Q3 25 | — | -5.1% | ||
| Q2 25 | — | -20.4% | ||
| Q1 25 | — | -14.4% | ||
| Q4 24 | — | -21.8% | ||
| Q3 24 | — | -20.1% | ||
| Q2 24 | — | -22.5% | ||
| Q1 24 | -899.0% | -6.7% |
每股收益（稀释后）IMVTMGLD
| Q4 25 | — | $-0.01 | ||
| Q3 25 | — | $-0.01 | ||
| Q2 25 | — | $-0.04 | ||
| Q1 25 | — | $-0.02 | ||
| Q4 24 | — | $-0.04 | ||
| Q3 24 | — | $-0.04 | ||
| Q2 24 | — | $-0.05 | ||
| Q1 24 | $-0.50 | $-0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $635.4M | $11.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $617.8M | $22.7M |
| 总资产 | $666.4M | $27.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资IMVTMGLD
| Q4 25 | — | $11.6M | ||
| Q3 25 | — | $12.5M | ||
| Q2 25 | — | $12.8M | ||
| Q1 25 | — | $15.6M | ||
| Q4 24 | — | $14.9M | ||
| Q3 24 | — | $17.5M | ||
| Q2 24 | — | $15.0M | ||
| Q1 24 | $635.4M | $16.1M |
股东权益IMVTMGLD
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $22.9M | ||
| Q2 25 | — | $23.0M | ||
| Q1 25 | — | $24.3M | ||
| Q4 24 | — | $23.4M | ||
| Q3 24 | — | $25.5M | ||
| Q2 24 | — | $26.6M | ||
| Q1 24 | $617.8M | $28.4M |
总资产IMVTMGLD
| Q4 25 | — | $27.8M | ||
| Q3 25 | — | $28.4M | ||
| Q2 25 | — | $30.4M | ||
| Q1 25 | — | $33.5M | ||
| Q4 24 | — | $33.0M | ||
| Q3 24 | — | $35.9M | ||
| Q2 24 | — | $32.9M | ||
| Q1 24 | $666.4M | $33.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-59.7M | $-908.0K |
| 自由现金流经营现金流 - 资本支出 | $-59.8M | — |
| 自由现金流率自由现金流/营收 | -714.4% | — |
| 资本支出强度资本支出/营收 | 1.8% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-214.6M | — |
8季度趋势，按日历期对齐
经营现金流IMVTMGLD
| Q4 25 | — | $-908.0K | ||
| Q3 25 | — | $-533.0K | ||
| Q2 25 | — | $-3.3M | ||
| Q1 25 | — | $-1.2M | ||
| Q4 24 | — | $-770.0K | ||
| Q3 24 | — | $-893.0K | ||
| Q2 24 | — | $-1.9M | ||
| Q1 24 | $-59.7M | $-658.0K |
自由现金流IMVTMGLD
| Q4 25 | — | — | ||
| Q3 25 | — | $-562.0K | ||
| Q2 25 | — | $-3.4M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-776.0K | ||
| Q3 24 | — | $-940.0K | ||
| Q2 24 | — | $-2.0M | ||
| Q1 24 | $-59.8M | — |
自由现金流率IMVTMGLD
| Q4 25 | — | — | ||
| Q3 25 | — | -8.1% | ||
| Q2 25 | — | -46.8% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -9.7% | ||
| Q3 24 | — | -11.9% | ||
| Q2 24 | — | -23.8% | ||
| Q1 24 | -714.4% | — |
资本支出强度IMVTMGLD
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.4% | ||
| Q2 25 | — | 0.7% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | 1.8% | 0.0% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IMVT
暂无分部数据
MGLD
| Fund Management Related Party | $4.6M | 60% |
| Food Products | $1.7M | 22% |
| Beauty Products | $1.2M | 15% |
| Other | $268.0K | 4% |
